Prevalence and risk factors of HSV-1 and HSV-2 antibodies in European HIV infected women

B H B van Benthem, J Spaargaren, J A R van den Hoek, J Merks, R A Coutinho, M Prins, and the European Study on the Natural History of HIV Infection in Women

Objectives: To investigate the prevalence and risk factors of HSV-1 and HSV-2 antibodies in HIV infected women and the association between recurrent genital ulcerations and HIV disease progression in HSV-2 positive women.

Methods: The presence of HSV antibodies was tested in 276 of the 487 women participating in a European cohort study of HIV infected women. Prevalence rate ratios described the association between HSV infection and its risk factors, using log binomial regression. Generalised estimating equations (GEE) analysis was performed to determine the impact of markers of HIV disease progression on recurrent genital ulcerations.

Results: The prevalence of HSV-1 and HSV-2 antibodies was 76% (95% confidence interval (95% CI): 71–81) and 42% (95% CI: 36–50); 30% (95% CI: 24–35) of the women had antibodies against both HSV-1 and HSV-2. The prevalence of HSV-1 was 86% (95% CI: 80–92) in southern Europe compared with 69% (95% CI: 57–79) and 67% (95% CI: 55–77) in central and northern Europe (p=0.002). This geographical variation remained after adjustment for other risk factors. An increasing number of years of sexual activity (p=0.0002) and a history of prostitution (p=0.0001) were independently associated with HSV-2 prevalence. In HSV-2 positive women, symptomatic cases of HSV infection were minimal, but increased with decreasing CD4 count.

Conclusion: In HIV infected women, the prevalence of HSV antibodies is high and symptomatic cases of HSV infection are minimal, but increase with decreasing CD4 count. HSV-2 but not HSV-1 was related to sexual behaviour (that is, a history of prostitution and the number of sexually active years) in this group of HIV infected women.

Introduction

Infection with herpes simplex viruses (HSV) is very common worldwide. In European countries, the estimated prevalence of HSV-1, determined by means of antibody measurements, varies between 60% and 90% in the general population, whereas the prevalence of HSV-2 ranges from 8% in pregnant women to 50% in homosexual men.1 Transmission of HSV-2 is more efficient from men to women than vice versa.2,3 Usually, HSV-1 infection occurs in childhood, causing mainly orolabial lesions, but it can occur with sexual transmission, causing genital herpes.1,5 HSV-2 infection, the major cause of genital herpes, is almost always sexually transmitted. After primary infection, both types remain latently present in the body and lead to the production of lifelong antibodies. A previous HSV-1 infection appears to provide a degree of protection against primary genital HSV-2 infection and its severity.1,3

The presence of genital herpes increases the risk for transmission of HIV.1,5 Only a minority of HSV-2 infected people develop clinical symptoms of HSV-2 infection and symptomatic HSV-2 shedding is more common in people co-infected with HIV than in HIV uninfected people.4,5,10 These findings indicate that a large proportion of HSV-2 infected individuals are unaware of their HSV-2 infection and are at risk of transmitting the agent. Risk factors for HSV-1 and HSV-2 prevalence in HIV infected people have not yet been studied. Therefore, the objectives of our study were to determine the prevalence and risk factors of HSV-1 and HSV-2 in a cohort of European women with HIV infection of known duration. Furthermore, we assessed the relation between HIV disease progression and the recurrence of genital ulcerations in HSV-2 infected women.

Methods

STUDY POPULATION

The European Study on the Natural History of HIV Infection in Women involves a prospective cohort of HIV infected women with a known interval of HIV seroconversion, as detailed elsewhere.11 Since 1993, 487 women from 31 centres in 12 European countries have been included. Follow up visits are scheduled every 6 months. At each visit, a standardised questionnaire is used to record various socio-demographic and sexual characteristics and a clinical examination, including a gynaecological examination, is performed. During each visit immunological (for example, CD4 count) and virological (for example, HIV-RNA levels) markers are determined. In 276 of the 487 women (57%), extra blood samples were taken at the first visit and during follow up and stored in the central repository of the European women’s study. Of these blood samples, we used the first available sample drawn in each case for the...
Prevalence and risk factors of HSV-1 and HSV-2 antibodies in European HIV infected women

The first available blood sample for each woman was tested for specific antibodies against HSV-1 and HSV-2. Analysis of HSV antibodies was performed with a commercial enzyme immunoassay (EIA, Gull Laboratories, Germany). An extinction ratio (compared with a control) above 1.5 was defined as seropositive, less than 0.8 as seronegative, and between 0.8 and 1.5 as intermediate. Samples with extinction ratios in the intermediate zone for either HSV-1 (n=34) or HSV-2 (n=38) were retested with a rapid immunoblot assay (RIBA, Chiron Corporation, CA, USA) used according to the manufacturer’s instructions.

Both tests were evaluated by our research group and were found to be suitable for epidemiological studies. Of the 34 intermediate HSV-1 samples, 25 were positive and nine were negative for HSV-1 antibodies with immunoblot. Of the 38 samples intermediate for HSV-2, 35 were reactive, and three turned out to be non-reactive to specific HSV-2 antigens.

Various sociodemographic and sexual characteristics as well as methodological risk factors were assessed by means of the questionnaire and were evaluated as risk factors for the prevalence of HSV-1 and HSV-2 antibodies. Sociodemographic risk factors included mode of HIV transmission (heterosexual intercourse, injecting drug use, other), geographic region, age at first vaginal intercourse, age at first sexual activity, marital status, and age at end of study entry, setting of the centre, year of the first HIV positive test, and year when the blood sample was drawn. All risk factors were categorised based on the median, tertiles, or quartiles, except the number of past sexual partners, which had been categorised in the questionnaire. Time dependent categorised risk factors were assessed by means of the questionnaire. Time dependent categorised risk factors were evaluated as risk factors for recurrence of genital ulcerations. These risk factors were CD4 counts and HIV-RNA levels. To ensure the right direction of cause and effect, CD4 counts and HIV-RNA levels were used from the visit preceding assessment of genital ulcerations.

Appendix A

Table 1 Prevalence of HSV-1 and HSV-2 antibodies in HIV infected women registered in the European Women Study

<table>
<thead>
<tr>
<th>HSV-1 antibodies</th>
<th>Negative No (%)</th>
<th>Positive No (%)</th>
<th>Total No (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>128 (46)</td>
<td>82 (30)</td>
<td>210 (76)</td>
</tr>
<tr>
<td>Total</td>
<td>160 (58)</td>
<td>116 (42)</td>
<td>276 (100)</td>
</tr>
</tbody>
</table>

Results

Among 276 HIV infected women, the prevalence of HSV-1 antibodies was 76% (95% CI (95% CI): 71.1–81.1), and the prevalence of HSV-2 antibodies was 42% (95% CI: 36.2–47.9) (table 1). The prevalence of the presence of both HSV-1 and HSV-2 antibodies was 30% (95% CI: 24.3–35.1). At the time of sampling, only 25% of the HSV-2 infected women and 13% of the HSV-1 infected women reported a history of genital herpes. Furthermore, 62% of the women who reported a history of genital herpes were HSV-2 positive, and 11% of the all HSV-2 positive women received antiviral HSV treatment at least once.

The prevalence and prevalence rate ratios of HSV-1 infection by geographic region are presented in table 2. Of all subjects living in southern Europe 86% were infected with HSV-1.
HSV-1 compared with 69% and 67% of all those living in central and northern Europe, respectively. This difference was statistically significant (p=0.002), even after adjustment for other risk factors. The presence HSV-1 antibodies was not related to sexual behaviour in this group of European HIV infected women, not even when the analysis was restricted to women under the age of 30 years. All other risk factors, including continent of birth, were not significantly associated with HSV-1 prevalence or confounded the association between HSV-1 infection and geographic region.

The results of univariable and multivariable analyses of HSV-2 infection are shown in table 3. In univariable analysis, the prevalence of HSV-2 antibodies was associated with the mode of HIV transmission, geographic region, age, and sexual behaviour. The presence of antibodies for HSV-1 decreased the likelihood of HSV-2 infection, although not significantly (prevalence rate ratio (PR): 0.76, 95% CI: 0.57–1.03). Women with a history of STD or prostitution had a higher risk of HSV-2 infection than women without such histories. In univariable analysis, the prevalence of HSV-2 antibodies increased significantly with increases in number of sexual partners and number of years of sexual activity. After adjustment for sexual behaviour, the effects of mode of HIV transmission, geographic region and age were no longer significant. In multivariable analysis, only the number of years of sexual activity and a history of prostitution remained independently and significantly associated with HSV-2 infection. Women with a history of prostitution had a 1.8-fold higher risk of HSV-2 infection than women without a history of prostitution. In addition, women who were sexually active for 20 years or more had an almost twofold higher risk of HSV-2 infection than women who were sexually active for less than 10 years. We found neither statistically significant confounding factors nor an interaction between history of prostitution and the number of years of sexual activity.

Overall, the number of recurrent genital ulcerations was low in HSV-2 positive women, even in immunosuppressed women (table 4). However, the recurrence of genital ulcerations was significantly higher in HSV-2 infected women with CD4 counts below 200 cells x10^6/l than in women with CD4 counts higher than 200 cells x10^6/l. In the 194 women with available HIV-RNA measurements, recurrent HSV infections increased with increasing number of HIV-RNA copies, although not significantly. These results did not change after adjustment for co-infection with HSV-1.

### Table 2: Risk factor independently associated with the presence of HSV-1 antibodies among 276 women registered in the European Women Study

<table>
<thead>
<tr>
<th>Geographical region</th>
<th>HSV-1 infection (%)</th>
<th>PR*</th>
<th>95% CI*</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>South</td>
<td>86</td>
<td>1.00</td>
<td></td>
<td>0.0017</td>
</tr>
<tr>
<td>Central</td>
<td>69</td>
<td>0.80</td>
<td>0.67–0.94</td>
<td></td>
</tr>
<tr>
<td>North</td>
<td>67</td>
<td>0.78</td>
<td>0.64–0.91</td>
<td></td>
</tr>
</tbody>
</table>

*PR = prevalence rate; CI = confidence interval estimated with log binomial regression analyses.

### Table 3: Risk factors associated with the presence of HSV-2 antibodies among 276 women registered in the European Women Study

<table>
<thead>
<tr>
<th>Mode of HIV transmission</th>
<th>HSV-2 positive (%)</th>
<th>Univariable</th>
<th>Multivariable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (%) *</td>
<td>OR†</td>
<td>95% CI†</td>
</tr>
<tr>
<td>CD4 count (&lt;10^6/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥200</td>
<td>7</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>&lt;200</td>
<td>8</td>
<td>4.87</td>
<td>1.53–15.5</td>
</tr>
<tr>
<td>HIV-RNA levels (copies/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤1000</td>
<td>1</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>1001–100 000</td>
<td>3</td>
<td>1.48</td>
<td>0.47–4.70</td>
</tr>
<tr>
<td>&gt;100 000</td>
<td>6</td>
<td>5.43</td>
<td>0.95–31.0</td>
</tr>
</tbody>
</table>

*No = number of clinically diagnosed genital ulcerations; (%) = percentage of visits with clinically diagnosed ulcerations. †OR = odds ratio; CI = confidence interval estimated with logistic regression for repeated measurements.
Discussion

To our knowledge, this is the first study to describe risk factors for HSV-1 and HSV-2 antibodies in HIV infected women. The prevalence of HSV-1 and HSV-2 antibodies in the HIV infected women included in the present study was 76% and 42%, respectively. The only independently associated risk factor of HSV-1 antibodies was geographic region. Our finding that the prevalence of HSV-1 antibodies is higher in southern Europe than in central and northern Europe is consistent with those of studies among various populations in several European countries, ranging from 60% among STD clinic attendees in Sweden up to 88% among women counselled in prenatal clinics in Italy. Geographic variation in the prevalence of HSV-1 antibodies might be explained by variation in socioeconomic factors during childhood, which we did not measure, such as family size and intimate family contact. Moreover, the presence HSV-1 antibodies was not related to sexual behaviour in this group of European HIV infected women. This lack of association is in contrast with the link found in recent studies between sexual behaviour and the presence of HSV-1 antibodies and with the suggestion that HSV-1 is of increasing importance as a cause of genital herpes.4 21 Women in our cohort were probably infected with HSV-1 by the time they became sexually active. Our results suggested that HSV-1 infection reduces the risk for HSV-2 infection, as was described by others.7 32 33

The prevalence of HSV-2 antibodies was strongly related to sexual behaviour. Women with a history of prostitution were at higher risk for HSV-2 infection than women without such a history. Furthermore, the prevalence increased with increasing number of sexually active years. Thus, in HIV infected women, the presence of HSV-2 antibodies may be used as a surrogate marker for sexual behaviour. These findings are consistent with those of studies among attendees of STD clinics23 24 and with population based surveys.25–27 Worldwide, there is some geographic variation in the prevalence of HSV-2—for example, a higher prevalence in the United States and Africa.2 25 26 However, we found no evidence for geographical variation within Western Europe.

Evidence was found for a relation between the recurrent genital ulcerations and markers of HIV disease progression. A decreasing CD4 count was associated with an increase in the recurrence of genital ulcerations in HSV-2 positive women. Recurrent genital ulcerations were more common in women with increased HIV-RNA levels, but the effect was not statistically significant. The recurrence of ulcerations increased with more advanced stages of HIV disease, as was found in a study among HIV infected prostitutes in Amsterdam.7 On the other hand, only a small proportion of HSV-2 infected women reported a history of genital herpes at the moment the blood sample used for HSV determination was obtained. This indicates that HSV-2 infection was present without symptoms in most of the HIV infected women included in this study. Since asymptomatic HSV shedding is (more) common in HIV positive than in HIV negative individuals, HIV infected women are at risk of transmitting HSV to their partners and neonates.10–32 Thus, their partners should use condoms to prevent against transmission of HIV as well as of HSV.

In HIV infected women of reproductive age, attention should be given to the possibility of vertical HSV transmission as well as HIV transmission.

Some limitations of this study should be noted. Firstly, a stored blood sample was available for only 276 of the 487 women included in the European women's study. Since women without a stored blood sample lived more often in northern Europe, it is likely that the prevalence of HSV-1 infection among all women included in the European women's study is lower. Risk factors of HSV-2 infection did not differ between women with and without a blood sample. Therefore, we assume that the results on HSV-2 prevalence in women with a stored blood sample are representative for the total group of women included in the European women's study. Secondly, the sensitivity of the EIA test we used was 95% for HSV-1 antibodies and varied between 98% and 99.7% for HSV-2 antibodies compared with western blots.13 33 In HIV infected people, the test could yield a false negative for some cases, which may have led to an underestimation of the true prevalence. However, we retested sera with an intermediate extinction ratio with RIBA, which increased the sensitivity for both infections.

In conclusion, the prevalence of HSV-1 and HSV-2 antibodies is high in this group of HIV infected women. The use of condoms by their partners could prevent transmission of both HIV and HSV. Attention to the possibility of vertical HSV transmission is necessary along with measures to prevent vertical HIV transmission. The prevalence of HSV-1 antibodies differs by geographic region, being more common in women living in southern Europe than in women living in northern and central Europe. HSV-2 infection is strongly related, whereas HSV-1 infection appears unrelated to sexual behaviour in HIV infected women. We found evidence for a relation between the recurrence of genital ulcerations and markers for HIV disease progression in HIV infected women who are also HSV-2 positive.

Sponsored by the DG XII of the European Commission, the French National Agency for AIDS research (ANRS), and the Dutch AIDS Foundation (Stichting AIDS Fonds, project 2171). We thank all women registered in the European study on the natural history of HIV infection in women for their ongoing participation, and Lucy Phillips, Ronald Geskus, and Arnaud Fontanet for their helpful comments and suggestions.

Contributors: BvB is the coordinator of the European Study on the Natural History of HIV Infection in Women. She performed the statistical analyses and prepared this manuscript; JS is head of the public health laboratory at which HSV tests were performed; AvdH is member of the steering committee of this study and she was involved in the design of the study; JM performed all the laboratory tests; MP is the project leader of the study and was involved in the statistical analyses; RC is the principal investigator of the study. All authors were involved in the preparation of the final manuscript.

There is no conflict of interest.
Appendix

COLLABORATORS ON THE EUROPEAN STUDY ON THE NATURAL HISTORY OF VIRUS INFECTION IN WOMEN

Yolanda Pelgrom, Institute of Tropical Medicine, Antwerp, Belgium; Birgit Bak-Knudsen, Hvidovre Hospital, Hvidovre, Denmark; Jorma Paavonen, Hannele Savonius, Department of Obstetrics and Gynecology, University of Helsinki, Finland; Catherine Marinou, Group d’Épidémiologie Clinique du SIDA en Aquitaine, Bordeaux, France; Marie-Emmanuelle Mars, La Conception Hospital, Marseilles, France; Jean-Albert Gastaut, Dominique Sparrando (steering committee); Paul Cesbron, Laennec Hospital, Creil, France; Marie-Laure Babut, Henri Mondor Hospital, Créteil, France; Anne Odier, private practitioner, Paris, France; Jean-Dominique Poveda, Pasteur Institute, Paris, France; Alain Berrebi, La Grave Hospital, Toulouse, France; Anastasia Roumeliotou, Athens School of Public Health, Greece; José Fiore, Aichirotopia Lepera, Bari University, Bari, Italy; Alberto Mattcelli, Anna Deltamia, Brescia University, Brescia, Italy; Alberto Agarossi, Mario Conti, Daniele Federici, Sacco Hospital, Milan, Italy; Annaraossa Del Mistro, Oncology Institute, Padova, Italy; Barbara Suligoi, Instituto Superior de Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università degli Studi di Sanità, Rome, Italy (steering committee); Karen Lindenburg, Joke Bax, Municipal Health Service, Amsterdam, The Netherlands; Elisabeth von der Lippe, Università gli...
Prevalence and risk factors of HSV-1 and HSV-2 antibodies in European HIV infected women

B H B van Benthen, J Spaargaren, J A R van den Hoek, J Merks, R A Coutinho and M Prins

*Sex Transm Infect* 2001 77: 120-124
doi: 10.1136/sti.77.2.120

Updated information and services can be found at:
http://sti.bmj.com/content/77/2/120

These include:

**References**
This article cites 26 articles, 15 of which you can access for free at:
http://sti.bmj.com/content/77/2/120#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Drugs: infectious diseases (3182)
- HIV / AIDS (2514)
- HIV infections (2514)
- HIV/AIDS (2514)
- Herpes simplex virus (229)
- Health education (960)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/